The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 28, 2015

Filed:

Dec. 17, 2010
Applicant:

Hubertus Hochrein, Munich, DE;

Inventor:

Hubertus Hochrein, Munich, DE;

Assignee:

Bavarian Nordic A/S, Kvistgaard, DK;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 63/00 (2006.01); A61K 45/00 (2006.01); C12P 21/00 (2006.01); C07K 14/53 (2006.01); C07K 14/555 (2006.01); C12N 15/117 (2010.01); A61K 35/15 (2015.01);
U.S. Cl.
CPC ...
C12N 15/117 (2013.01); A61K 35/15 (2013.01); C12N 2310/17 (2013.01);
Abstract

In the present invention, CD8+ conventional dendritic cells (CD8+ cDCs) and equivalents thereof (eCD8+ cDCs) in mouse and human have been established as major source of IFN-lambda (IFN-λ) in response to double-stranded (ds) nucleic acids. The invention relates to therapeutic applications of ds nucleic acids or analogs thereof targeting CD8+ and/or eCD8+ cDCs in the prevention and/or treatment of infectious diseases, preferably viral infections, or cancer. Furthermore, the invention relates to an in vitro method for producing IFN-λ and/or generating or obtaining a population of IFN-λ producing CD8+ or eCD8+ cDCs as well as in vitro method for detecting or screening for CD8+ and/or eCD8+ cDCs. In addition, the invention relates to a Flt3-ligand or a M-CSF receptor ligand for use in increasing the level of CD8+ and/or eCD8+ cDCs in a subject suffering from an infectious disease or cancer.


Find Patent Forward Citations

Loading…